Receive Breaking News updates as they occur
Rebels bombarded government-held areas of Aleppo with rockets on Tuesday, killing 19 people and hitting a hospital, while also launching a ground assault on army-held positions of the divided city, the Syrian Observatory for Human Rights said. The Syrian army said insurgents had launched a broad-based assault and that it was responding. The army statement said the attack was at "a time when international and local efforts are being made to shore up the (cessation of hostilities agreement) and to implement ... calm in Aleppo".
By David Ingram NEW YORK (Reuters) - Former drug executive Martin Shkreli, who last year became a lightning rod for outrage over soaring prescription drug prices, may face additional U.S. charges of securities fraud, a federal prosecutor said on Tuesday. More charges related to Shkreli's involvement with biopharmaceutical company Retrophin Inc could be filed within a month, Assistant U.S. Attorney Winston Paes said at a hearing in federal court in Brooklyn, New York. Shkreli, 33, sparked outrage among patients, medical societies and U.S. lawmakers after another company he ran, Turing Pharmaceuticals, raised the price of the drug Daraprim by more than 5,000 percent to $750 a pill.